---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-21-022540"
form_type: "8-K"
ticker: "SEER"
cik: "0001726445"
company_name: "Seer, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:52:17.623943+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Seer Q3 2021 revenue $2.2M, net loss $18.4M; on track for broad release in early 2022

## Summary
- Revenue $2.2M vs $72K in Q3 2020; product-related revenue $1.6M including $787K from related party.
- Gross margin 54%; operating expenses $19.6M (up from $8.5M) due to higher compensation and public company costs.
- Net loss $18.4M vs $8.2M; cash and investments $506.6M as of Sept 30, 2021.
- Added new Limited Release customers; on track for high single-digit total; broad release expected early 2022.
- Customer studies: Oregon Health (prostate cancer, 500-1000 samples), Broad Institute (proteome depth), Sanford Burnham (TMT), Protein Metrics (glycoproteome).

## SEC filing metadata
- accession: 0001628280-21-022540
- form_type: 8-K
- ticker: SEER
- cik: 0001726445
- company_name: Seer, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1726445/000162828021022540/0001628280-21-022540-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1726445/000162828021022540/seer-20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-21-022540
- JSON: https://secwatch.observer/filing/0001628280-21-022540.json
- Plain text: https://secwatch.observer/filing/0001628280-21-022540.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.